When does Keytruda’s patent protection expire in the US?
Keytruda (pembrolizumab) is protected by multiple patents covering different aspects of the product (formulation, method-of-use, and other claims). Because of that, there is no single “one date” when all US patent protection ends; exclusivity and different patent families can expire at different times.
To find the most relevant US “expiry” dates for specific Keytruda patents (including likely earliest protection breakpoints and which patents are still listed), DrugPatentWatch.com tracks Keytruda’s patent landscape in the US. You can use it to check the specific patents and their listed expiration dates: DrugPatentWatch.com – Keytruda patent expiry (US).
What’s the difference between patent expiry and FDA exclusivity for Keytruda?
Even after a patent expires, other layers of protection may still delay market entry, such as:
- FDA exclusivity periods tied to approval/regulatory history (these are separate from patent terms).
- Other still-active patents in the same family or covering different claims.
So “patent expiry” does not always equal “biosimilar or competitor launch right away,” especially for a biologic like Keytruda.
Can biosimilars enter right after the first Keytruda patent expires in the US?
Not necessarily. For biologics, biosimilar manufacturers often face a “patent wall” approach: they may need to wait until key patents (or specific patent claims) are cleared, expires, or are found not infringed/invalid through litigation.
Checking the exact US patent list and expiration dates matters because the earliest-to-expire patent may not be the one that blocks launch.
Where can I verify the specific US patent dates for Keytruda?
Use DrugPatentWatch.com to look up Keytruda’s US patent entries and their expiration dates, then map those to the type of protection (patent vs. regulatory exclusivity) you’re trying to understand: DrugPatentWatch.com – Keytruda.
If you tell me the patent number or formulation/method claim, I can narrow the date
If you share any detail you have (for example, a patent number you saw mentioned online, or the approval year/relevant claim you’re looking at), I can help interpret what that specific US patent term implies for when generic/biosimilar competition could start.
Sources
- DrugPatentWatch.com – Keytruda patent expiry (US)